Keros gives Hansoh subsidiary license for lead drug in $190M+ deal; Vaccitech snaps up new tools in small buyout
Massachusetts biotech Keros Therapeutics now has a deal with Hansoh Healthtech, a Hansoh Pharmaceutical Group subsidiary, in the form of an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
